Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for imlunestrant, an oral selective estrogen receptor degrader (SERD), at the San Antonio Breast Cancer Symposium (SABCS) from December 10-13. This late-breaking presentation marks the first time EMBER-3 data will be publicly shared. EMBER-3 is evaluating imlunestrant as […]
Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a critical earnings report that highlighted missed revenue targets for two of its most anticipated drugs: Mounjaro, a diabetes medication, and Zepbound, a high-profile weight-loss drug. Investors, who had anticipated a robust sales report amid growing demand for […]
Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, and Taltz. The revenue spike includes a notable $579.0 million from the Baqsimi rights sale. Excluding this sale and 2022’s COVID-19 antibodies, the Q2 2023 revenue surged by 22%. Key […]
Eli Lilly and Company (Lilly) has bagged the abemaciclib FDA approval to treat advanced breast cancer in patients whose breast cancer had progressed after taking therapy that changed their hormones (endocrine therapy).
Eli Lilly and Company (Lilly) has announced receiving U.S. Food and Drug Administration (FDA) approval for Verzenio (abemaciclib), to treat patients with metastatic breast cancer who have seen progression after previous treatment. This recent approval allows for the use of Verzenio in combination with fulvestrant in patients whose cancer has advanced on endocrine therapy. Detailed […]